Periodontal RegenerationPhase 2RCTNCT04786327
Minimally Invasive Flap With Platelet Rich Fibrin or Growth Factor Enhanced Matrix in Treatment of Intrabony Defect
A Phase 2 study testing Minimal invasive flap technique, Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin and minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S in people with Periodontal Regeneration, run by Tanta University at 1 site in Egypt.
Trial summary
Twenty-one intra-bony defects in fifteen systemically healthy patients with moderate to severe chronic periodontitis were randomly classified into 3 groups, 7 sites each. Group І treated by MIST alone, group ІІ treated by MIST + ethylenediamine-tetraaceticacid (EDTA) + PRF and group III treated by MIST + EDTA + GEM… Read more about this study
- Who is it for?
- Ages 30 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontal Regeneration
- What is being tested?
- Minimal invasive flap technique, Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin and minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 21 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2018to 1 Oct 2019
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Presence of at least one tooth with PPD and CAL loss of ≥ 5 mm associated with an intra-bony defect of ≥ 2 mm according to Cortellini and Tonetti, 2007
Who cannot join
- Patients with uncontrolled or poorly controlled diabetes, life-threatening conditions, or requiring antibiotic prophylaxis were excluded.
- Smokers
- Pregnant patients.
- Patients with aggressive periodontitis.
- Patients with multiple interconnected vertical defect walls.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Intrabony Defects Management Using Growth Factor Enhanced Matrix Versus Platelet Rich Fibrin Utilizing Minimally Invasive Surgical Technique. A Randomized Clinical and Radiographic Trial.
Twenty-one intra-bony defects in fifteen systemically healthy patients with moderate to severe chronic periodontitis were randomly classified into 3 groups, 7 sites each. Group І treated by MIST alone, group ІІ treated by MIST + ethylenediamine-tetraaceticacid (EDTA) + PRF and group III treated by MIST + EDTA + GEM 21S. The clinical parameters including probing pocket depth (PPD), clinical attachment level (CAL) and bleeding on probing (BOP), were recorded at baseline, 3, 6 and 9 months post-surgery. Cone beam computed tomography (CBCT) was performed at baseline and 9 months post-surgery to evaluate bone level and bone density
Read the detailed description
: Twenty-one intra-bony defects in fifteen systemically healthy patients with moderate to severe chronic periodontitis were randomly classified into 3 groups, 7 sites each. Group І treated by MIST alone, group ІІ treated by MIST + ethylenediamine-tetraaceticacid (EDTA) + PRF and group III treated by MIST + EDTA + GEM 21S. The clinical parameters including probing pocket depth (PPD), clinical attachment level (CAL) and bleeding on probing (BOP), were recorded at baseline, 3, 6 and 9 months post-surgery. Cone beam computed tomography (CBCT) was performed at baseline and 9 months post-surgery to evaluate bone level and bone density.
- Conditions
- Periodontal Regeneration
- Being tested
- Minimal invasive flap technique, Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin, minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S
- Keywords
- Chronic periodontitis, Intra-bony defects, Minimally invasive surgical technique, Platelet rich fibrin,, Growth factor enhanced matrix 21S
- Medical subject headings
- Chronic Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Minimal invasive flap techniqueProcedure or surgery
Also called regenerative surgery
contained defect treated with Minimally invasive flap
Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrinProcedure or surgery
Also called regenerative surgery
contained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft
minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21SCombination product
Also called regenerative surgery
contained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect
| Study group | Role | What they receive |
|---|---|---|
| treated by using Minimally invasive flap only. | Placebo comparator | 7 sites treated with Minimally invasive flap only Receives: Procedure: Minimal invasive flap technique |
| Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin . | Experimental | 7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of platelet rich fibrin graft Receives: Procedure: Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin |
| MIST with root conditioning (EDTA) and GEM 21S . | Experimental | 7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of growth factor enhanced matrix GEM21S Receives: Combination Product: minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S |
What is being measured
The primary outcome is the main question the study is designed to answer.
the change in probing pocket depth
the change in probing pocket depth was measured at baseline, 3,6 and 9 months evaluation period using periodontal probe
Measured: 9 months
the change bleeding on probing score
the change in bleeding on probing measured at baseline,3,6 and 9 months evaluation period
Measured: 9 months
the change Clinical attachment level
the change in Clinical attachment level measured at baseline, 3,6 and 9 months using the periodontal probe
Measured: 9 months
Cone beam radiograph
Cone beam radiograph for measuring the change in area of the defect, depth of the depth and bone density at baseline, 3, 6 and 9 month post operative treatment using OnDemand software of cone beam
Measured: 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Mar 2021
- Study start1 Jan 2018
- Primary completion1 Oct 2019
- Study completion1 Oct 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal RegenerationStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, malak mohamed shoukheba, Tanta University
- Investigators
- malak m shoukheba, phd, Principal investigator, tanta university faculty of dentistry
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04786327
- Sponsor's protocol ID
- 4
- Acronym
- RCT
- Status last verified
- Jun 2021
- First submitted
- 25 Feb 2021
- Last updated
- 18 Jun 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intrabony Defects Management Using Growth Factor Enhanced Matrix Versus Platelet Rich Fibrin Utilizing Minimally Invasive Surgical Technique. A Randomized Clinical and Radiographic Trial.
- ClinicalTrials.gov ID
- NCT04786327
- Acronym / sponsor ID
- RCT / 4
- Conditions
- Periodontal Regeneration
- Keywords
- Chronic periodontitis, Intra-bony defects, Minimally invasive surgical technique, Platelet rich fibrin,, Growth factor enhanced matrix 21S
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 1 Oct 2019 (actual)
- Study completion
- 1 Oct 2019 (actual)
- First posted
- 8 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Twenty-one intra-bony defects in fifteen systemically healthy patients with moderate to severe chronic periodontitis were randomly classified into 3 groups, 7 sites each. Group І treated by MIST alone, group ІІ treated by MIST + ethylenediamine-tetraaceticacid (EDTA) + PRF and group III treated by MIST + EDTA + GEM 21S. The clinical parameters including probing pocket depth (PPD), clinical attachment level (CAL) and bleeding on probing (BOP), were recorded at baseline, 3, 6 and 9 months post-surgery. Cone beam computed tomography (CBCT) was performed at baseline and 9 months post-surgery to evaluate bone level and bone density
Detailed description
: Twenty-one intra-bony defects in fifteen systemically healthy patients with moderate to severe chronic periodontitis were randomly classified into 3 groups, 7 sites each. Group І treated by MIST alone, group ІІ treated by MIST + ethylenediamine-tetraaceticacid (EDTA) + PRF and group III treated by MIST + EDTA + GEM 21S. The clinical parameters including probing pocket depth (PPD), clinical attachment level (CAL) and bleeding on probing (BOP), were recorded at baseline, 3, 6 and 9 months post-surgery. Cone beam computed tomography (CBCT) was performed at baseline and 9 months post-surgery to evaluate bone level and bone density.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| treated by using Minimally invasive flap only. | Placebo comparator | Procedure: Minimal invasive flap technique7 sites treated with Minimally invasive flap only |
| Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin . | Experimental | Procedure: Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of platelet rich fibrin graft |
| MIST with root conditioning (EDTA) and GEM 21S . | Experimental | Combination Product: minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S7 sites treated with Minimally invasive flap plus EDTA root conditioning and application of growth factor enhanced matrix GEM21S |
Who may qualify
- Ages
- 30 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Presence of at least one tooth with PPD and CAL loss of ≥ 5 mm associated with an intra-bony defect of ≥ 2 mm according to Cortellini and Tonetti, 2007
Key exclusion criteria (5 listed)
- Patients with uncontrolled or poorly controlled diabetes, life-threatening conditions, or requiring antibiotic prophylaxis were excluded.
- Smokers
- Pregnant patients.
- Patients with aggressive periodontitis.
- Patients with multiple interconnected vertical defect walls.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Minimal invasive flap techniqueAlso: regenerative surgerycontained defect treated with Minimally invasive flap | Procedure or surgery | treated by using Minimally invasive flap only. |
| Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrinAlso: regenerative surgerycontained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft | Procedure or surgery | Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin . |
| minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21SAlso: regenerative surgerycontained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect | Combination product | MIST with root conditioning (EDTA) and GEM 21S . |
Primary outcome
the change in probing pocket depth
Time frame: 9 months
the change in probing pocket depth was measured at baseline, 3,6 and 9 months evaluation period using periodontal probe
the change bleeding on probing score
Time frame: 9 months
the change in bleeding on probing measured at baseline,3,6 and 9 months evaluation period
the change Clinical attachment level
Time frame: 9 months
the change in Clinical attachment level measured at baseline, 3,6 and 9 months using the periodontal probe
Cone beam radiograph
Time frame: 9 months
Cone beam radiograph for measuring the change in area of the defect, depth of the depth and bone density at baseline, 3, 6 and 9 month post operative treatment using OnDemand software of cone beam
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2021.
- Individual participant dataSharing planned: No
Related trials for Periodontal Regeneration
Active, not recruiting
L-PRF Block vs Composite Graft for Horizontal Ridge Augmentation
Alveolar Ridge Resorption After Extraction, Alveolar Bone Loss
Not yet recruitingEarly Phase 1
The Efficacy of Exosomes Combined With Synthetic Bone Graft for the Treatment of Periodontal Intra-bony Defects
Intra-Bony Defects in Periodontitis Patients
Not yet recruitingPhase 1/2
Alveolar Ridge Preservation (ARP) Study Using Alloplastic Biomaterial and a Resorbable Synthetic Membrane. A Digital Workflow (CBCT/Scanner) Evaluates Hard and Soft Tissue Volumetric Changes at 4 Months, Validating Support for the Gingival Phenotype and Buccal Bone Plate.
Alveolar Ridge Augmentation, Bone Substitutes
Not yet recruitingObservational study
Effects of Standard PRP and Extracellular Vesicle-Enriched PRP on Human Gingival Fibroblasts
Periodontal Regeneration, Wound Healing
Recruiting
Bone Marrow Mononuclear Cells for the Repair of Severe Maxillofacial Bone Defects
Maxillofacial Bone Defect, Alveolar Bone Loss
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
malak m shoukheba, phd principal investigator
tanta university faculty of dentistry
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Minimal invasive flap technique, Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin and minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S in people with Periodontal Regeneration, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the change in probing pocket depth (time frame: 9 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2021.